共 162 条
[1]
Kris MG(2006)American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006 J Clin Oncol 24 2932-2947
[2]
Hesketh PJ(2004)Evaluation of potential inductive effects of aprepitant on cytochrome P450 3A4 and 2C9 activity J Clin Pharmacol 44 215-223
[3]
Somerfield MR(2003)Effects of aprepitant on cytochrome P450 3A4 activity using midazolam as a probe Clin Pharmacol Ther 74 150-156
[4]
Feyer P(2003)Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects Clin Ther 25 1407-1419
[5]
Clark-Snow R(2006)Lack of effect of aprepitant on hydrodolasetron pharmacokinetics in CYP2D6 extensive and poor metabolizers J Clin Pharmacol 46 792-801
[6]
Koeller JM(2005)Pharmacokinetics of palonosetron in combination with aprepitant in healthy volunteers Curr Med Res Opin 21 595-601
[7]
Morrow GR(1989)Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochromes P-450: studies in rats and patients J Clin Invest 3 688-697
[8]
Chinnery LW(2000)In vivo and in vitro induction of human cytochrome P4503A4 by dexamethasone Clin Pharmacol Ther 68 356-366
[9]
Chesney MJ(2001)Use of the erythromycin breath test for in vivo assessments of cytochrome P4503A activity and dosage individualization Clin Pharmacol Ther 70 305-310
[10]
Gralla RJ(1999)Failure of erythromycin breath test to correlate with midazolam clearance as a probe of cytochrome P4503A Clin Pharmacol Ther 66 224-231